EGFR and cancer: Bioinformatics has been instrumental in pinpointing immunotherapy targets like Programmed Death Ligand 1 (PD-L1) (Han et al., 2020) and in identifying biomarkers for epidermal growth factor receptor (EGFR) inhibitors in non-small cell lung cancer (Prabhakar, 2015), as well as poly (ADP-ribose) polymerase (PARP) inhibitors for cancers with Breast Cancer Gene 1/2 (BRCA1/2) mutations (Faraoni and Graziani, 2018).